This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow An author's correction has been published
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yong, D.
Right arrow Articles by Rhee, J. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yong, D.
Right arrow Articles by Rhee, J. K.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, January 2004, p. 352-357, Vol. 48, No. 1
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.1.352-357.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

In Vitro Activities of DA-7867, a Novel Oxazolidinone, against Recent Clinical Isolates of Aerobic and Anaerobic Bacteria

Dongeun Yong,1 Jong Hwa Yum,1 Kyungwon Lee,1* Yunsop Chong,1 Sung Hak Choi,2 and Jae Keol Rhee2

Department of Laboratory Medicine, Research Institute of Bacterial Resistance, and Brain Korea 21 Project for Medical Sciences, Yonsei University College of Medicine, Seoul,1 Research Laboratory, Dong-A Pharmaceutical Co., Ltd., Yongin, Korea2

Received 8 August 2003/ Returned for modification 5 September 2003/ Accepted 25 September 2003

In vitro activities of DA-7867, a novel oxazolidinone, were compared to those of linezolid and commonly used antimicrobials. DA-7867 had the lowest MIC for 90% of the aerobic gram-positive bacterial strains tested, <=0.25 µg/ml, and it was more potent than linezolid.

* Corresponding author. Mailing address: Department of Laboratory Medicine, Yonsei University College of Medicine, 134 Shinchondong, Seodaemunku, Seoul 120-752, Korea. Phone: 82-2-361-5866. Fax: 82-2-313-0908. E-mail: leekcp{at}yumc.yonsei.ac.kr.

Antimicrobial Agents and Chemotherapy, January 2004, p. 352-357, Vol. 48, No. 1
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.1.352-357.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Vera-Cabrera, L., Castro-Garza, J., Rendon, A., Ocampo-Candiani, J., Welsh, O., Choi, S. H., Blackwood, K., Molina-Torres, C. (2005). In Vitro Susceptibility of Mycobacterium tuberculosis Clinical Isolates to Garenoxacin and DA-7867. Antimicrob. Agents Chemother. 49: 4351-4353 [Abstract] [Full Text]  
  • Yoon, E. J., Jo, Y. W., Choi, S. H., Lee, T. H., Rhee, J. K., Yoo, M., Shim, M. J., Choi, E. C. (2005). In Vitro and In Vivo Activities of DA-7867, a New Oxazolidinone, against Aerobic Gram-Positive Bacteria. Antimicrob. Agents Chemother. 49: 2498-2500 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»